The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for voxelotor (Oxbryta®) for the treatment of sickle cell disease in patients aged 4 to 11 years
Always Be a Step Ahead
Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.
Subscribe to AMI's Insights Newsletter Today.